1. Balakrishnan, Ashwini, Goodpaster, Tracy, Randolph-Habecker, Julie, Porter, Peggy L, Riddell, Stanley R. 2016. Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues. In Clinical cancer research : an official journal of the American Association for Cancer Research, 23, 3061-3071. doi:10.1158/1078-0432.CCR-16-2083. https://pubmed.ncbi.nlm.nih.gov/27852699/
2. Parker, Barbara A, Shatsky, Rebecca A, Schwab, Richard B, Yau, Christina, Kipps, Thomas J. 2023. Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial. In Breast cancer research and treatment, 199, 281-291. doi:10.1007/s10549-023-06914-2. https://pubmed.ncbi.nlm.nih.gov/37029329/
3. Srivastava, Shivani, Salter, Alexander I, Liggitt, Denny, Rader, Christoph, Riddell, Stanley R. . Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting. In Cancer cell, 35, 489-503.e8. doi:10.1016/j.ccell.2019.02.003. https://pubmed.ncbi.nlm.nih.gov/30889382/
4. Lin, Weiwei, Niu, Rui, Park, Seong-Min, Park, Jong Bae, Yin, Jinlong. 2023. IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2-CREB signaling axis. In Nature communications, 14, 1578. doi:10.1038/s41467-023-37306-1. https://pubmed.ncbi.nlm.nih.gov/36949068/
5. Hojjat-Farsangi, Mohammad, Moshfegh, Ali, Daneshmanesh, Amir Hossein, Osterborg, Anders, Mellstedt, Håkan. 2014. The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy. In Seminars in cancer biology, 29, 21-31. doi:10.1016/j.semcancer.2014.07.005. https://pubmed.ncbi.nlm.nih.gov/25068995/
智鼠故事 
